menu
    • menu
    [{"orgOrder":0,"company":"Ionetix","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Ionetix \/ Ionetix"},{"orgOrder":0,"company":"Ionetix","sponsor":"NAYA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Partnership","leadProduct":"NY-703","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Ionetix \/ Ionetix"},{"orgOrder":0,"company":"Ionetix","sponsor":"Convergent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu PSMA-I&T","moa":"||PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ionetix \/ Ionetix","highestDevelopmentStatusID":"7","companyTruncated":"Ionetix \/ Ionetix"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ Precision Molecular"}]

    Find Clinical Drug Pipeline Developments & Deals by Ionetix

    Menu

    Ionetix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NAYA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NAYA Therapeutics Partners With IONETIX for Astatine-211 Targeted Alpha Therapies

                            Details : The partnership aims to supply Astatine-211 for NAYA's Lead Therapy, NY-703, GPC3-targeting ²¹¹At candidate, aiming to Enter Clinical Trials for Residual & Metastatic hepatocellular carcinoma.

                            Product Name : NY-703

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            August 21, 2025

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NAYA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T,68-Ga PSMA-11

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Convergent Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-22...

                            Details : The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            May 25, 2022

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T,68-Ga PSMA-11

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Convergent Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PMI21

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Precision Molecular

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211

                            Details : Astatine-211 is a high-energy alpha-emitting radioisotope that can have a very powerful therapeutic effect when combined with the right targeting molecule. PMI is developing an astatine-211 labeled inhibitor of prostate-specific membrane antigen (PSMA) k...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : PMI21

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Precision Molecular

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Ionetix

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT2001,225-Ac

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

                            Details : PDS Biotechnology licenses National Cancer Institute for intellectual property related to tumor-associated active T-cell receptor gamma. The administration of PDS0102, Versamune-TARP tumor antigen combination, led to induction of large numbers of tumor t...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            November 09, 2021

                            Lead Product(s) : PNT2001,225-Ac

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth